| Symbol | NDRA |
|---|---|
| Name | ENDRA LIFE SCIENCES INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Address | 3600 GREEN COURT,SUITE 350, ANN ARBOR, Michigan, 48105, United States |
| Telephone | +1 734 335-0468 |
| Fax | — |
| — | |
| Website | https://www.endrainc.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001681682 |
| Description | ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures. Additional info from NASDAQ: |
New Form 425 - ENDRA Life Sciences Inc. <b>Filed:</b> 2026-08-17 <b>AccNo:</b> 0001213900-26-090755 <b>Size:</b> 94 KB
Read moreENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Read moreNew Form 425 - ENDRA Life Sciences Inc. <b>Filed:</b> 2026-07-22 <b>AccNo:</b> 0001477932-26-004439 <b>Size:</b> 80 KB
Read moreNew Form 425 - ENDRA Life Sciences Inc. <b>Filed:</b> 2026-07-22 <b>AccNo:</b> 0001477932-26-004434 <b>Size:</b> 56 KB
Read moreJoin the Live Investor Webinar for Noble Africa, the Proposed ASP Isotopes Spin-Out Creating a Public Helium Company
Read moreNew Form 425 - ENDRA Life Sciences Inc. <b>Filed:</b> 2026-07-17 <b>AccNo:</b> 0001477932-26-004369 <b>Size:</b> 30 KB
Read moreNew Form 425 - ENDRA Life Sciences Inc. <b>Filed:</b> 2026-07-17 <b>AccNo:</b> 0001213900-26-078913 <b>Size:</b> 31 KB
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.
Read moreNew Form SCHEDULE 13D/A - ENDRA Life Sciences Inc. <b>Filed:</b> 2026-06-29 <b>AccNo:</b> 0001213900-26-073318 <b>Size:</b> 61 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04302051 | Assessment of Fatty Liver With Thermo-acoustic Device | — | NASH | Withdrawn | 2023-11-02 | 2026-07-09 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| MRI-PDFF estimation of hepatic fat | Other | Preclinical | NASH | WITHDRAWN | NCT04302051 |
| Thermo-acuostic image acquisition of liver | Other | Preclinical | NASH | WITHDRAWN | NCT04302051 |
| MRI-PDFF estimation of hepatic fat | Other | Preclinical | NASH | WITHDRAWN | NCT04302051 |
| Thermo-acuostic image acquisition of liver | Other | Preclinical | NASH | WITHDRAWN | NCT04302051 |